Clinical Trial Update: Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating continued efficacy and safety of zoledronic acid given every 4 weeks versus every 12 weeks in the second year of treatment for patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2014-08-04